1
|
Castanon A, Duffield S, Ramagopalan S, Reynolds R. Why is target trial emulation not being used in health technology assessment real-world data submissions? J Comp Eff Res 2024; 13:e240091. [PMID: 38850128 DOI: 10.57264/cer-2024-0091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2024] Open
Affiliation(s)
| | - Stephen Duffield
- National Institute of Health & Care Excellence, Manchester, M1 4BT, UK
| | | | | |
Collapse
|
2
|
Arora P, Gupta A, Mackay E, Heeg B, Thorlund K. The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2024; 27:999-1002. [PMID: 38636697 DOI: 10.1016/j.jval.2024.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 03/20/2024] [Accepted: 04/08/2024] [Indexed: 04/20/2024]
Abstract
OBJECTIVES The Inflation Reduction Act (IRA), enacted in 2022, brings substantial reforms to the US healthcare system, particularly regarding Medicare. A key aspect includes the introduction of Medicare price negotiation. The objective of this commentary is to explore the implications of the IRA for US pharmaceutical companies, with a specific focus on the role of real-world evidence (RWE) in the context of Medicare reforms. METHODS This commentary uses a qualitative analysis of the IRA's provisions related to healthcare and pharmaceutical regulation, focusing on how these reforms change the evidence requirements for pharmaceutical companies. It discusses the methodological aspects of generating and using RWE, including techniques such as target trial emulation and quantitative bias analysis methods to address biases inherent in RWE. RESULTS This commentary highlights that the IRA introduces a unique approach to value assessment in the United States by evaluating drug value several years after launch, as opposed to at launch, similar to health technology assessments in other regions. It underscores the central role of RWE in comparing drug effectiveness across diverse clinical scenarios to improve the accuracy of real-world data comparisons. Furthermore, this article identifies key methodologies for managing the inherent biases in RWE, which are crucial for generating credible evidence for IRA price negotiations. CONCLUSIONS This article underscores the importance of these methodologies in ensuring credible evidence for IRA price negotiations. It advocates for an integrated approach in evidence generation, positioning RWE as pivotal for informed pricing discussions in the US healthcare landscape.
Collapse
Affiliation(s)
- Paul Arora
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
| | - Alind Gupta
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
| | | | | | | |
Collapse
|
3
|
Castanon A, Sloan R, Arocha LS, Ramagopalan SV. EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out? J Comp Eff Res 2024; 13:e240052. [PMID: 38696698 PMCID: PMC11145525 DOI: 10.57264/cer-2024-0052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2024] [Accepted: 04/15/2024] [Indexed: 05/04/2024] Open
Affiliation(s)
| | | | | | - Sreeram V Ramagopalan
- Lane Clark & Peacock LLP, London, W1U 9DQ, UK
- Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK
| |
Collapse
|
4
|
Fernandez J, Babin C, Thomassin C, Pelon F, Kelley S, Cochat P, Galbraith M, Berdaï D, Pariente A, Salvo F, Vanier A. Can requests for real-world evidence by the French HTA body be planned? An exhaustive retrospective case-control study of medicinal products appraisals from 2016 to 2021. Int J Technol Assess Health Care 2024; 40:e33. [PMID: 38757153 DOI: 10.1017/s0266462324000291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/18/2024]
Abstract
OBJECTIVES In France, decisions for pricing and reimbursement for medicinal products are based on appraisals performed by the National authority for health (Haute Autorité de Santé (HAS)). During the appraisal process, additional real-world evidence can be requested as "Post-Registration Studies" (PRS) when there are uncertainties in evidence that could be resolved by additional data collection. To facilitate PRS planning, a retrospective exploratory analysis was conducted to identify the characteristics of medicinal products associated with a PRS request. METHODS This analysis encompassed all appraisals finalized between January 1, 2016 and December 31, 2021 and compared products for which the appraisal led to a PRS request with those that did not. RESULTS Six hundred positive opinions for reimbursement were identified, with a PRS request present in 17 percent (n = 103) of cases. The independent characteristics associated with a PRS request were a mild or moderate clinical benefit score, a major to moderate or minor clinical added value score, previous availability under an early access program, and certain therapeutic areas (neurology, pulmonology, and endocrinology). These findings suggest two different profiles of PRS requests: (i) products for which there is uncertainty in the size of the clinical benefit and (ii) innovative products for which a substantial benefit is expected but uncertainties persist. CONCLUSIONS These results will assist health technology developers to better anticipate data generation to promptly address uncertainties identified by HAS. It may also help HAS and other assessment agencies to work together to improve postlaunch evidence generation according to the characteristics of the medicinal products.
Collapse
Affiliation(s)
- Judith Fernandez
- HTA Department, Haute Autorité de Santé, La Plaine Saint-Denis, France
| | - Céleste Babin
- HTA Department, Haute Autorité de Santé, La Plaine Saint-Denis, France
| | - Camille Thomassin
- HTA Department, Haute Autorité de Santé, La Plaine Saint-Denis, France
| | - Floriane Pelon
- HTA Department, Haute Autorité de Santé, La Plaine Saint-Denis, France
| | - Sophie Kelley
- HTA Department, Haute Autorité de Santé, La Plaine Saint-Denis, France
| | - Pierre Cochat
- Scientific Board and Chairman of the Transparency Committee, Haute Autorité de Santé, La Plaine Saint-Denis, France
| | | | - Driss Berdaï
- CHU de Bordeaux, Pharmacoepidemiology and Appropriate use of Medicine Team, Public Health Department, Clinical Pharmacology Unit Bordeaux, Nouvelle-Aquitaine, France
| | - Antoine Pariente
- CHU de Bordeaux, Pharmacoepidemiology and Appropriate use of Medicine Team, Public Health Department, Clinical Pharmacology Unit Bordeaux, Nouvelle-Aquitaine, France
- University of Bordeaux, INSERM, BPH, U1219, Team AHeaD Talence, Aquitaine, France
| | - Francesco Salvo
- University of Bordeaux, INSERM, BPH, U1219, Team AHeaD Talence, Aquitaine, France
- CHU de Bordeaux, Regional center for pharmacovigilance Public Health Department, Clinical Pharmacology Unit Bordeaux, Nouvelle-Aquitaine, France
| | - Antoine Vanier
- HTA Department, Haute Autorité de Santé, La Plaine Saint-Denis, France
- Université de Tours, UMR U1246 Sphere, Inserm Tours, Centre-Val de Loire, France
| |
Collapse
|
5
|
Orbach D, Carton M, Khadir SK, Feuilly M, Kurtinecz M, Phil D, Vokuhl C, Koscielniak E, Pierron G, Lemelle L, Sparber-Sauer M. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study). ESMO Open 2024; 9:103006. [PMID: 38657345 PMCID: PMC11061226 DOI: 10.1016/j.esmoop.2024.103006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 03/21/2024] [Accepted: 03/21/2024] [Indexed: 04/26/2024] Open
Abstract
BACKGROUND Patients with infantile fibrosarcoma (IFS) have shown strong and long-lasting responses to larotrectinib, a tropomyosin receptor kinase inhibitor (TRKi), in single-arm clinical trials. Conventional chemotherapy has also shown important efficacy. But, until now, no comparative data exist. This study aims to assess the therapeutic benefit of larotrectinib over the current standard of care (SOC) of chemotherapy in paediatric patients with locally advanced or metastatic IFS. PATIENTS AND METHODS EPI VITRAKVI is a retrospective, observational, externally controlled study (NCT05236257). Data of patients aged ≤21 years with locally advanced or metastatic IFS treated with larotrectinib in the phase I/II SCOUT trial (NCT02637687) were compared with those of an external historical control group (data of Institut Curie and Cooperative Weichteilsarkom Studiengruppe) treated with a chemotherapy-based regimen. Between-group differences were assessed after balancing groups using inverse probability of treatment weighting (IPTW). RESULTS In total, 93 patients were compared, 51 in the larotrectinib arm and 42 in the external control arm. After therapy, 4 patients (7.8%) in the larotrectinib group had a medical treatment failure event [start of new systemic treatment (2 cases), mutilating surgery (2 cases)] versus 15 (35.7%) in the external control group [start of new systemic treatment (6 cases), mutilating surgery (5 cases), radiation therapy (2 cases), and death (2 cases)]. Larotrectinib was associated with an 80% reduced likelihood of encountering a medical treatment failure event, when compared to the external control group (weighted and stratified hazard ratio 0.20, 95% confidence interval 0.06-0.63, P = 0.0060). These results were confirmed by sensitivity analyses, including exact matching, and subgroup analyses for number of lines of treatment. CONCLUSIONS Treatment with larotrectinib reduced the need of subsequent therapies compared to SOC with chemotherapy in children with locally advanced or metastatic IFS, regardless of the line of treatment.
Collapse
Affiliation(s)
- D Orbach
- SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris.
| | - M Carton
- Biometry Unit, Institut Curie, PSL Research University, Paris
| | | | - M Feuilly
- Bayer HealthCare SAS, La Garenne-Colombes, France
| | | | - D Phil
- Bayer U.S. LLC, Whippany, USA
| | - C Vokuhl
- Section of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn
| | - E Koscielniak
- Klinikum der Landeshauptstadt Stuttgart gKAöR, Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Stuttgart; Medizinische Fakultät der Universität Tübingen, Tübingen, Germany
| | - G Pierron
- Genetic Somatic Unit, PSL Research University, Institut Curie, Paris, France
| | - L Lemelle
- SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris
| | - M Sparber-Sauer
- Klinikum der Landeshauptstadt Stuttgart gKAöR, Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Stuttgart; Medizinische Fakultät der Universität Tübingen, Tübingen, Germany
| |
Collapse
|
6
|
Boccara F, Sabouret P, Boileau C, Georges JL, Leclercq C, Lesnik P, Bruckert E. Establishing a multi-specialty consensus in the clinical need for hypercholesterolemia management and its implication for patients access to innovative therapies. Panminerva Med 2024; 66:18-26. [PMID: 37851332 DOI: 10.23736/s0031-0808.23.04999-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2023]
Abstract
BACKGROUND Increased level of blood LDL-C has a causal and cumulative effect on advancing atherosclerotic cardiovascular diseases (ASCVD). European guidelines for treating high LDL-C levels have been recently updated. However, in France, several challenges (e.g., physician and patient awareness, healthcare management) limit the application of management guidelines. The aim of this study was to understand the current opinions and perceived unmet clinical needs in recognising and managing hypercholesterolemia as an ASCVD risk factor, and to explore consensus around factors that support the effective management of elevated LDL-C. METHODS An expert group of cardiologists, endocrinologists, biology/genetics researchers, and a health technology assessments expert, from France was convened. The current management of hypercholesterolemia and barriers to achieving LDL-C goals in France were discussed and 44 statements were developed. Wider consensus was assessed by sending the statements as a 4-point Likert Scale questionnaire to cardiologists and endocrinologists across France. The consensus threshold was defined as ≥75%. RESULTS A total of 101 responses were received. Consensus was very high (>90%) in 25 (57%) statements, high (≥75%) in 18 (41%) statements and was not achieved (<75%) only in 1 (2%) of statements. Overall, 43 statements achieved consensus. CONCLUSIONS Based on consensus levels, key recommendations for improving current guidelines and approaches to care have been developed. Implementation of these recommendations will lead to better concordance with international treatment guidelines and increase levels of education for healthcare practitioners and patients. In turn, this will improve the available treatment pathways for cardiovascular diseases, potentially creating improved patient outcomes in the future.
Collapse
Affiliation(s)
- Franck Boccara
- Department of Cardiology, Saint-Antoine Research Center, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR S938, Saint-Antoine Hospital, Hôpitaux de l'Est Parisien, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France -
| | - Pierre Sabouret
- Service of Cardiology, Institute of Cardiology, Pitié-Salpêtrière University Hospital, Sorbonne University, Paris, France
| | - Catherine Boileau
- Department of Genetics, LVTS - Institut National de la Santé et de la Recherche Médicale (INSERM) U1148, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France
| | - Jean-Louis Georges
- Service of Cardiology, Center Hospitalier de Versailles, Le Chesnay, France
- Annales de Cardiologie et Angéiologie, Elsevier Masson SAS, Issy les Moulineaux, France
| | - Christophe Leclercq
- Service of Cardiology, Rennes University Hospital, University of Rennes, Rennes, France
| | - Philippe Lesnik
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR_S 1166, Pitié-Salpêtrière University Hospital, Sorbonne University, Paris, France
| | | |
Collapse
|
7
|
Chen S, Tikhonovsky N, Dhanji N, Ramagopalan S. Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2024; 27:265-267. [PMID: 38135213 DOI: 10.1016/j.jval.2023.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 11/17/2023] [Indexed: 12/24/2023]
Affiliation(s)
- Simon Chen
- Health Analytics, Lane Clark & Peacock LLP, London, England, UK
| | | | - Nishit Dhanji
- Health Analytics, Lane Clark & Peacock LLP, London, England, UK
| | - Sreeram Ramagopalan
- Health Analytics, Lane Clark & Peacock LLP, London, England, UK; Centre for Pharmaceutical Medicine Research, King's College London, England, UK.
| |
Collapse
|
8
|
Luu VP, Fiorini M, Combes S, Quemeneur E, Bonneville M, Bousquet PJ. Challenges of artificial intelligence in precision oncology: public-private partnerships including national health agencies as an asset to make it happen. Ann Oncol 2024; 35:154-158. [PMID: 37769849 DOI: 10.1016/j.annonc.2023.09.3106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 07/13/2023] [Accepted: 09/17/2023] [Indexed: 10/03/2023] Open
Affiliation(s)
- V P Luu
- Epidemiology and innovation Unit, Artificial Intelligence and Cancers Association, Paris, France.
| | - M Fiorini
- Artificial Intelligence and Cancers Association, Paris, France
| | | | - E Quemeneur
- France Biotech, Paris, France; Transgene S.A., Illkirch-Graffenstaden, France
| | - M Bonneville
- Alliance pour la Recherche et l'Innovation des Industries de Santé, Paris, France; Institut Mérieux, Lyon, France
| | - P J Bousquet
- Health Survey, Data-Science, Assessment Division, Institut National du Cancer, Boulogne Billancourt, France; Aix Marseille University, INSERM, IRD, Economics and Social Sciences Applied to Health & Analysis of Medical Information (SESSTIM), Marseille, France
| |
Collapse
|
9
|
Naudet F, Patel CJ, DeVito NJ, Le Goff G, Cristea IA, Braillon A, Hoffmann S. Improving the transparency and reliability of observational studies through registration. BMJ 2024; 384:e076123. [PMID: 38195116 DOI: 10.1136/bmj-2023-076123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2024]
Affiliation(s)
- Florian Naudet
- CHU Rennes, Inserm, Institut de Recherche en Santé, Environnement et Travail-UMR_S 1085, University of Rennes, Rennes, France
- Institut Universitaire de France, Paris, France
| | - Chirag J Patel
- Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA
| | - Nicholas J DeVito
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
| | | | - Ioana A Cristea
- Department of General Psychology, University of Padova, Padova, Italy
| | | | - Sabine Hoffmann
- Department of Statistics, Ludwig-Maximilians-Universität München, Munich, Germany
- Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany
| |
Collapse
|
10
|
Lemaitre F, Florentin V, Blin O, Bayle A, Benito S, Chauny JV, Galaup A, Korchagina D, Lang M, Le Tourneau C, Pelloux H, Picard N, Guilhaumou R. Comment faire entrer la médecine de précision dans la décision thérapeutique de routine au lit du malade ? Therapie 2024; 79:1-11. [PMID: 38129247 DOI: 10.1016/j.therap.2023.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Accepted: 10/19/2023] [Indexed: 12/23/2023]
Affiliation(s)
- Florian Lemaitre
- Inserm, EHESP, Institut de recherche en santé, environnement et travail (Irset) - UMR S 1085, université de Rennes, CHU de Rennes, 35000 Rennes, France.
| | - Virginie Florentin
- Direction médecine personnalisée, Roche SAS, 92600 Boulogne-Billancourt, France
| | - Olivier Blin
- Inserm 1106, service de pharmacologie clinique et pharmacosurveilleance, en delegation Tafalgie Therapeutics, UMR, Aix-Marseille université, AP-HM, 13385 Marseille, France
| | - Arnaud Bayle
- Bureau biostatistique et epidémiologie, Gustave-Roussy, université Paris-Saclay, 94800 Villejuif, France; Inserm, CESP U1018 Oncostat, labelisé Ligue contre le cancer, université Paris-Saclay, 94800 Villejuif, France
| | | | - Jean-Vannak Chauny
- Direction accès au marché & affaires publiques, Amgen, 92100 Boulogne-Billancourt, France
| | | | | | | | - Christophe Le Tourneau
- Institut Curie, 75000 Paris, France; Inserm U900, 92210 Saint-Cloud, France; Université Paris-Saclay, 75005 Paris, France
| | - Hervé Pelloux
- Parasitology-Mycology laboratory, University Grenoble-Alpes, University Hospital Grenoble-Alpes, 38043 Grenoble, France
| | - Nicolas Picard
- Service de pharmacologie, toxicologie et pharmacovigilance, centre de biologie et de recherche en santé (CBRS), CHU de Limoges, 87042 Limoges, France
| | | |
Collapse
|
11
|
Bray BD, Ramagopalan SV. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14. J Comp Eff Res 2024; 13:e230189. [PMID: 38179957 PMCID: PMC10842288 DOI: 10.57264/cer-2023-0189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 12/19/2023] [Indexed: 01/06/2024] Open
Abstract
In this latest update we highlight: a publication from the US FDA regarding the definitions of real-world data (RWD) and real-world evidence (RWE); a publication from academic researchers on a demonstration project for target trial emulation; a publication from the National Institute of Health and Care Excellence (NICE) on the 1 year anniversary of their RWE framework; and a publication from NICE and Flatiron Health on the utility of US RWD for initial UK health technology assessment decision making.
Collapse
Affiliation(s)
- Benjamin D Bray
- Lane Clark & Peacock LLP, London, W1U 1DQ, UK
- Department of Population Health Sciences, King's College London, London, SE1 9NH, UK
| | - Sreeram V Ramagopalan
- Lane Clark & Peacock LLP, London, W1U 1DQ, UK
- Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 1UL, UK
| |
Collapse
|
12
|
Leahy TP, Durand-Zaleski I, Sampietro-Colom L, Kent S, Zöllner Y, Coyle D, Casadei G. The role of quantitative bias analysis for nonrandomized comparisons in health technology assessment: recommendations from an expert workshop. Int J Technol Assess Health Care 2023; 39:e68. [PMID: 37981828 DOI: 10.1017/s0266462323002702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2023]
Abstract
The use of treatment effects derived from nonrandomized studies (NRS) in health technology assessment (HTA) is growing. NRS carry an inherently greater risk of bias than randomized controlled trials (RCTs). Although bias can be mitigated to some extent through appropriate approaches to study design and analysis, concerns around data availability and quality and the absence of randomization mean residual biases typically render the interpretation of NRS challenging. Quantitative bias analysis (QBA) methods are a range of methods that use additional, typically external, data to understand the potential impact that unmeasured confounding and other biases including selection bias and time biases can have on the results (i.e., treatment effects) from an NRS. QBA has the potential to support HTA bodies in using NRS to support decision-making by quantifying the magnitude, direction, and uncertainty of biases. However, there are a number of key aspects of the use of QBA in HTA which have received limited discussion. This paper presents recommendations for the use of QBA in HTA developed using a multi-stakeholder workshop of experts in HTA with a focus on QBA for unmeasured confounding.
Collapse
Affiliation(s)
| | - Isabelle Durand-Zaleski
- AP-HP, Health Economics Research Unit, Department of Public Health, Henri Mondor Hospital, Paris, France
- Methods, UMRS 1153, French National Institute of Health and Medical Research, Paris, France
- Faculty of Medicine, Université Paris Est Creteil, Creteil, France
| | - Laura Sampietro-Colom
- Health Technology Assessment (HTA) Unit, Hospital Clinic of Barcelona, Barcelona, Spain
| | | | - York Zöllner
- Department of Health Sciences, HAW Hamburg, Hamburg, Germany
| | - Doug Coyle
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada
| | - Gianluigi Casadei
- Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
| |
Collapse
|
13
|
Serret-Larmande A, Zenati B, Dechartres A, Lambert J, Hajage D. A methodological review of population-adjusted indirect comparisons reveals inconsistent reporting and suggests publication bias. J Clin Epidemiol 2023; 163:1-10. [PMID: 37717707 DOI: 10.1016/j.jclinepi.2023.09.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 09/07/2023] [Accepted: 09/11/2023] [Indexed: 09/19/2023]
Abstract
OBJECTIVES Population-adjusted indirect comparisons (PAICs) were developed in the 2010s to allow for comparisons between two treatments evaluated in different trials while accounting for differences in patient characteristics if individual patient data (IPD) are available for only one trial. Such comparisons are increasingly used in market access applications when a pharmaceutical company compares its new treatment (with IPD available) to another treatment developed by a competitor (with only aggregated data available). This study aimed to describe the characteristics of these PAICs, assess their methodology, and describe the reported results. STUDY DESIGN AND SETTING Original articles reporting the use of at least one PAIC were searched on PubMed between January 1, 2010 and April 2, 2022. Two reviewers independently selected articles and extracted data. RESULTS We included 133 publications reporting the results of 288 PAICs. Half of the articles were published on or after May 7, 2020, and 71 (53%) pertained to onco-hematology. The pharmaceutical industry was involved in 130 (98%) articles. Key methodological aspects were reported inconsistently, with only three articles adequately reporting all aspects. A total of 161 (56%) articles reported a statistically significant benefit for the treatment evaluated on IPD. Conversely, only one PAIC significantly favored the treatment evaluated on aggregated data. CONCLUSION Although the number of published PAICs is increasing, the methodology and transparency need to be improved. Moreover, our study strongly suggests a reporting bias. This situation calls for strengthening guidelines to improve trust in PAIC results and thus their reliability in market access applications.
Collapse
Affiliation(s)
- Arnaud Serret-Larmande
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie, Sorbonne Université, Paris, France; ECSTRRA Team UMR-1153 INSERM, AP-HP Saint Louis Hospital, Université Paris Cité, Paris, France.
| | - Belkacem Zenati
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie, Sorbonne Université, Paris, France
| | - Agnès Dechartres
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie, Sorbonne Université, Paris, France
| | - Jérôme Lambert
- ECSTRRA Team UMR-1153 INSERM, AP-HP Saint Louis Hospital, Université Paris Cité, Paris, France
| | - David Hajage
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie, Sorbonne Université, Paris, France
| |
Collapse
|
14
|
Bray B, Ramagopalan SV. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12. J Comp Eff Res 2023; 12:e230092. [PMID: 37345541 PMCID: PMC10508304 DOI: 10.57264/cer-2023-0092] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Accepted: 05/26/2023] [Indexed: 06/23/2023] Open
Abstract
In this latest update we highlight the final results from the RCT-DUPLICATE initiative, the publication of guidance from Haute Autorité de Santé (HAS), the joint viewpoint from the Institute for Quality and Efficiency in HealthCare (IQWIG) and the Belgian HealthCare Knowledge Center, and a position from the European Organization for Research and Treatment of Cancer (EORTC). Finally, we discuss how the NICE RWE framework has been implemented to allow consideration of RWE external control arms.
Collapse
Affiliation(s)
- Ben Bray
- Lane Clark & Peacock, London, W1U 1DQ, UK
- Department of Population Health Sciences, King’s College London, London, SE1 3QD, UK
| | - Sreeram V Ramagopalan
- Lane Clark & Peacock, London, W1U 1DQ, UK
- Center for Pharmaceutical Medicine Research, King’s College London, London, SE1 9NH, UK
| |
Collapse
|